End-of-Treatment FDG PET-CT (EOT-PET) in Patients with Post-Chemotherapy Masses for Seminoma: Can We Avoid Further Intervention?

  SFX Search  Permissions and Reprints Abstract

Context Patients with seminoma present with advanced disease. End-of-treatment (EOT) positron emission tomography-computed tomography (PET-CT) is done to assess response and direct management of post-chemotherapy residual masses.

Purpose This article assesses the utility of EOT PET-CT in the management of post-chemotherapy residual lymph nodal masses seminoma.

Materials and Methods We analyzed all patients with seminoma who underwent an EOT PET-CT from January 2015 to January 2020 at our center and calculated the positive predictive value (PPV) and negative predictive value (NPV) of EOT PET-CT in the entire cohort of patients and among subgroups.

Results A total of 34 male patients underwent EOT PET-CT. Fourteen (41.2%) were stratified as good risk and 20 (58.8%) as intermediate risk. The median follow-up was 23 months (interquartile range: 9.75–53 months). In 23 patients there were residual masses of size more than 3 cm at the EOT PET scan. EOT PET was positive as per the SEMPET criteria in 18 (78%) out of 23 patients. None underwent retroperitoneal lymph node dissection. All four who underwent image-guided biopsy, showed only necrosis on pathology. One patient with positive mediastinal node (standardized uptake value 13.6) had granulomatous inflammation. There was no relapse or progression during this period of follow-up. The NPV for EOT PET-CT for the entire cohort, > 3 cm, and > 6 weeks cutoff were 100%, respectively. The PPV for EOT PET-CT for the entire cohort, > 3 cm residual mass, and > 6 weeks cutoff were 8.7, 11.11, and 6.67%, respectively.

Conclusion EOT PET-CT has a low PPV and high NPV in predicting viable tumor in post-chemotherapy residual masses among patients with seminomatous germ cell tumors. If required, EOT PET positivity can be confirmed by a biopsy or reassessed with a repeat PET-CT imaging to document persistent disease prior to further intervention.

Keywords seminoma - PET-CT - germ cell tumor - post-chemotherapy residual masses Authors' Contributions

Anjana Joel: Conceptualization, methodology, formal analysis, investigation, writing - original draft, and visualization.


Ashish Singh: Conceptualization, methodology, formal analysis, investigation, writing - review and editing, visualization, and supervision.


Julie Hepzibah: Conceptualization, methodology, formal analysis, investigation, writing - review and editing, visualization, project administration, and funding acquisition.


Antony Devasia: Conceptualization, methodology, formal analysis, investigation, writing - review and editing, visualization, and supervision.


Santosh Kumar: Conceptualization, methodology, formal analysis, investigation, writing - review and editing, visualization, and supervision.


Birla Roy Gnanamuthu: Conceptualization, methodology, formal analysis, investigation, writing - review and editing, and visualization.


Anuradha Chandramohan: Conceptualization, methodology, formal analysis, investigation, writing - review and editing, and visualization.


Arun Jacob Philip George: Conceptualization, methodology, formal analysis, investigation, writing - review and editing, and visualization


Nirmal Thampi John: Conceptualization, methodology, formal analysis, investigation, writing - review and editing, and visualization.


Bijesh Yadav: Formal analysis, data curation, and software.


Ajoy Oommen John: Conceptualization, methodology, formal analysis, writing - review and editing, and visualization.


Josh Thomas Georgy: Formal analysis, investigation, writing - original draft, and visualization.


Subhashini John: Formal analysis, investigation, writing - original draft, and visualization.


Raju Titus Chacko: Conceptualization, methodology, formal analysis, investigation, writing - review and editing, visualization, supervision, project administration, and funding acquisition.

Publication History

Article published online:
22 August 2022

© 2022. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

留言 (0)

沒有登入
gif